Table 2 Resource use, cost-effectiveness and cost of time in inactive disease during first year from onset of therapy in JIA
IFX | TRIPLE | MTX | |
|---|---|---|---|
Resource | |||
Mean, € (SD) | |||
Cost of bDMARDsa | 6781 (2420) | 291 (1020) | 1200 (4089) |
Total medication costs | |||
Original | 12,182 (4246) | 1040 (1290) | 2230 (2867) |
Biosimilar | 7204 (2472) | 952 (960) | 1953 (2517) |
Intra-articular injections | |||
in general anesthesia | 2556 (2225) | 3745 (2169) | 4815 (1985) |
in local anesthesia | 118 (315) | 101 (188) | 236 (331) |
Intravenous administration | 4095 (688) | 193 (614) | 429 (912) |
Health care visits | |||
Rheumatologist | 1754 (534) | 1893 (446) | 1823 (420) |
Ophtalmologist | 849 (272) | 1050 (344) | 1036 (400) |
Dentist | 379 (589) | 170 (327) | 454 (530) |
General practitioner | 66 (113) | 58 (108) | 75 (156) |
Physiotherapy | 943 (693) | 1331 (1158) | 2217 (1226) |
Other therapy | 177 (205) | 265 (287) | 468 (409) |
Hospital admission days | 90 (293) | 60 (261) | 299 (659) |
Gray scale radiography | 70 (105) | 59 (93) | 170 (194) |
Magnetic resonance imaging | 167 (296) | 100 (238) | 416 (505) |
Total Health care costs | |||
Original infliximab | 23,512 (4077) | 10,244 (4908) | 15,349 (6782) |
Biosimilar infliximab | 18,533 (3126) | 10,093 (4580) | 14,963 (6461) |
Work loss | 1667 (1701) | 1363 (1515) | 2239 (2660) |
Travel Expenses | 963 (202) | 681 (257) | 1008 (358) |
Total costs, societal perspective | |||
Original | 26,142 (4801) | 12,288 (5545) | 18,686 (8872) |
Biosimilar | 21,164 (4158) | 12,136 (5286) | 18,300 (8635) |
Mean Cumulative QALYsb | 0.758 (0.065) | 0.735 (0.062) | 0.666 (0.124) |
Mean cum time in CID, weeks | 24.8 (17.7) | 13.3. (14.4) | 6.2 (8.9) |
Incremental differencesc | IFX vs TRIPLE | TRIPLE vs MTX | IFX vs MTX |
Incremental total costsd (95%CI) | |||
Original | 12,516 (11,219 to 13,850) | − 6164 (− 8086 to − 4303) | 6353 (4585 to 7999) |
Biosimilar | 8833 (7209 to 9494) | −6164 (− 8086 to − 4303) | 2169 (382 to 3754) |
Incremental QALYs e | 0.030 (0.014 to 0.045) | 0.039 (0.021 to 0.056) | 0.069 (0.053 to 0.084) |
ICER, € | IFX vs TRIPLE | TRIPLE vs MTX | IFX vs MTX |
Original | 417,200 | Dominante | 92,072 |
Biosimilar | 294,433 | Dominante | 31,435 |
Cost per additional month spent in CID, € e | |||
IFX vs Triple | TRIPLE vs MTX | IFX vs MTX | |
Original | 5282 | Dominantf | 1765 |
Biosimilar | 3442 | Dominantf | 678 |